Browse impact reports

639+ reports from charities, CICs and nonprofits across the UK

All 639
Arts, Culture & Heritage 22 Community & Social Justice 322 Education & Young People 239 Environment & Climate 39 Health & Wellbeing 352 Housing & Homelessness 59 Poverty & Inclusion 125 Sport & Physical Activity 88
Filtered by: × Health & Wellbeing

Search results

Showing 352 reports
Sort by
2023
Girlguiding

Girlguiding Impact Report 2023

300,000+ girls aged 4–18 active members across the UK
Key Metric 1
70,000 volunteers supporting local units
Key Metric 2
Girls in Girlguiding are 28% more confident than the UK average and 15% happier
Key Metric 3
Girls aged 10–15 report up to 23% higher confidence than the UK average for girls
Education & Young People Mental Health
View
2024
Solace Women's Aid

Annual Report and Financial Statements 2023/24

18,862 people's lives touched by Solace services; 14,435 adults and children supported in frontline services
Key Metric 1
£14.4 million income to run services; 266 staff; 7,197 volunteer hours
Key Metric 2
809 women and children provided safe accommodation across 24 refuges and 64 move-on spaces
Key Metric 3
92% of service users rated Solace services as good, very good or excellent; 89% found it easy or very easy to make initial contact
Community & Social Justice Children
View
2025
SafeLives

Impact Report 2024–25

1,100 service users referred to the Drive Project in 2024/25; over 7,000 total since launch
Key Metric 1
New 2025–2028 strategy launched, co-created with survivors and professionals
Key Metric 2
Victims and Prisoners Act became law; SafeLives secured renewed Home Office investment to expand Drive Project across England and Wales
Key Metric 3
Independent evaluations of Drive Project show significant reductions in abusive behaviours, reduced risk to victim-survivors, and reduced repeat perpetrator cases at MARAC
Community & Social Justice Children
View
2025
Breast Cancer Now

Annual Report and Accounts 2024/25

Record income of £59.3 million in 2024/25 (up 48% since 2019/20)
Key Metric 1
£34.6 million invested in research, support and campaigns; £16 million committed to research alone
Key Metric 2
325 of the world's leading breast cancer researchers supported; 12,240 helpline calls and 3,905 messages answered
Key Metric 3
5,263 people with primary breast cancer and 1,063 with secondary breast cancer supported through tailored services (up 15% and 27% respectively)
Health & Wellbeing Health
View
Sponsored

Need a stronger report submission?

Upgrade to a paid monthly tier to add your logo, priority placement, and deeper storytelling.

View pricing
2025
Women's Health Matters

Annual Report and Financial Statements 2024/25

1,702 women and girls worked with directly in 2024/25 (up from 1,554 the previous year)
Key Metric 1
979 group sessions, 1,744 one-to-one sessions and 164 crèche sessions delivered
Key Metric 2
311 children directly supported; a further 1,226 children impacted indirectly
Key Metric 3
100% of staff reported feeling confident in the leadership and direction of the organisation, valued in their contributions, and would recommend WHM as a good place to work
Health & Wellbeing Poverty
View
2025
Ovarian Cancer Action

Annual Report 2024–25

264,000 people accessed the OCA website in 2024/25
Key Metric 1
Nearly 200,000 people reached through Ovarian Cancer Awareness Month campaign
Key Metric 2
Over 10,000 people completed the genetic risk tool
Key Metric 3
World-first ovarian cancer vaccine (OvarianVax) development unlocked, with Cancer Research UK funding secured; potential to move to human clinical trials within five years
Health & Wellbeing Prevention
View
2025
Myeloma UK

Myeloma UK Impact Report 2025: For today and for tomorrow

Multiple NHS drug approvals secured in 2025 including world-first BVD approval, benefitting thousands of myeloma patients
Key Metric 1
UK's leading myeloma charity working to prevent, treat and help people live well with myeloma through research, advocacy and patient support
Key Metric 2
Funding pioneering research, securing NHS treatment access, supporting patients and carers, and raising awareness of myeloma symptoms and precursor conditions
Key Metric 3
IsaVRD quadruplet treatment approved in England, Wales and Scotland — 63% of patients still in remission after five years in trials
Health & Wellbeing Research
View